Analysts think CELC stock price could increase by 126%
Feb 18, 2025, 12:25 PM
-18.25%
What does CELC do
Celcuity, based in Minneapolis, employs 55 staff and went public on September 20, 2017. Its lead candidate, gedatolisib, targets specific cancer pathways and is in trials for advanced breast and prostate cancer.
8 analysts think CELC stock price will increase by 125.70%. The current median analyst target is $29.07 compared to a current stock price of $12.88. The lowest analysts target is $27.27 and the highest analyst target is $44.10.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
